tbuckley/cabot-search huggingface dataset:
HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies
Authors: Hibiki Udagawa, Monique B. Nilsson, Jacqulyne P. Robichaux, Junqin He, Alissa Poteete, Hong Jiang, Simon Heeke, Yasir Y. Elamin, Yuji Shibata, Shingo Matsumoto, Kiyotaka Yoh, Shogo Okazaki, Takashi Masuko, Igor Odintsov, Romel Somwar, Marc Ladanyi, Koichi Goto, John V. Heymach
Journal: Journal of Thoracic Oncology (2023)
A Revolving Door to the Intensive Care Unit for Children Surviving Acute Respiratory Distress Syndrome
Authors: Elizabeth Y. Killien
Journal: JAMA Network Open (2023)

Garrett Keim, MD, MSCE; Jesse Y. Hsu, PhD; Neethi P. Pinto, MD; Megan L. McSherry, MD; Annie Laurie Gula, MD; Jason D. Christie, MD, MSCE; Nadir Yehya, MD, MSCE
Associations of Apixaban Dose With Safety and Effectiveness Outcomes in Patients With Atrial Fibrillation and Severe Chronic Kidney Disease
Authors: Yunwen Xu, Alexander R. Chang, Lesley A. Inker, Mara McAdams-DeMarco, Morgan E. Grams, Jung-Im Shin
Journal: Circulation (2023)

BACKGROUND: Recommendations for apixaban dosing on the basis of kidney function are inconsistent between the US Food and Drug Administration and European Medicines Agency for patients with atrial fibrillation. Optimal apixaban dosing in chronic kidney disease remains unknown. METHODS: With the use of deidentified electronic health record data from the Optum Labs Data Warehouse, patients with atrial fibrillation and chronic kidney disease stage 4/5 initiating apixaban between 2013 and 2021 were identified. Risks of bleeding and stroke/systemic embolism were compared by apixaban dose (5 versus 2.5 mg), adjusted for baseline characteristics by the inverse probability of treatment weighting. The Fine-Gray subdistribution hazard model was used to account for the competing risk of death. Cox regression was used to examine risk of death by apixaban dose. RESULTS: Among 4313 apixaban new users, 1705 (40%) received 5 mg and 2608 (60%) received 2.5 mg. Patients treated with 5 mg apixaban were younger (mean age, 72 versus 80 years), with greater weight (95 versus 80 kg) and higher serum creatinine (2.7 versus 2.5 mg/dL). Mean estimated glomerular filtration rate was not different between the groups (24 versus 24 mL·min –1 ·1.73 m –2 ). In inverse probability of treatment weighting analysis, apixaban 5 mg was associated with a higher risk of bleeding (incidence rate 4.9 versus 2.9 events per 100 person-years; incidence rate difference, 2.0 [95% CI, 0.6–3.4] events per 100 person-years; subdistribution hazard ratio, 1.63 [95% CI, 1.04–2.54]). There was no difference between apixaban 5 mg and 2.5 mg groups in the risk of stroke/systemic embolism (3.3 versus 3.0 events per 100 person-years; incidence rate difference, 0.2 [95% CI, –1.0 to 1.4] events per 100 person-years; subdistribution hazard ratio, 1.01 [95% CI, 0.59–1.73]), or death (9.9 versus 9.4 events per 100 person-years; incidence rate difference, 0.5 [95% CI, –1.6 to 2.6] events per 100 person-years; hazard ratio, 1.03 [95% CI, 0.77–1.38]). CONCLUSIONS: Compared with 2.5 mg, use of 5 mg apixaban was associated with a higher risk of bleeding in patients with atrial fibrillation and severe chronic kidney disease, with no difference in the risk of stroke/systemic embolism or death, supporting the apixaban dosing recommendations on the basis of kidney function by the European Medicines Agency, which differ from those issued by the US Food and Drug Administration.
Primary Angiosarcoma of Lumbar Pedicle and Transverse Process Revealed by FDG PET/CT
Authors: Pei Yang, Liu Xiao, Lin Li
Journal: Clinical Nuclear Medicine (2023)

Abstract The primary angiosarcoma of bone is rare. It typically occurs in tubular bones, pelvis, and trunk. However, its occurrence in the lumbar pedicle, and transverse process is infrequent. Thus, we present the imaging findings of FDG PET/CT in a rare case of primary angiosarcoma of lumbar pedicle and transverse process. It presented as solitary osteolytic bone destruction in the right pedicle and transverse process of L4 with intense FDG uptake. This case added knowledge of another rare occurrence site of primary angiosarcoma of bone, which should be considered as a differential diagnosis when we meet similar image appearance on FDG PET/CT.
Global Trends in Highly Cited Studies in COVID-19 Research
Authors: Satoshi Funada, Takashi Yoshioka, Yan Luo, Toshi Iwama, Chikako Mori, Naofumi Yamada, Hideki Yoshida, Kota Katanoda, Toshi A. Furukawa
Journal: JAMA Network Open (2023)

Since the onset of the COVID-19 outbreak, an extremely high number of studies have been published worldwide, with variable quality. Research trends of highly cited papers may enable identification of influential research, providing insights for new research ideas; it is therefore important to investigate trends and focus on more influential publications in COVID-19-related studies.To examine research trends of highly cited studies by conducting a bibliometric analysis of highly cited studies in the previous 2 months about COVID-19.In this cross-sectional study, Essential Science Indicators (ESI) and Web of Science (WOS) Core Collection were used to find studies with a focus on COVID-19 that were identified as highly cited studies from Clarivate Analytics. Highly cited studies were extracted from the ESI database bimonthly between January 2020 and December 2022. Bibliographic details were extracted from WOS and combined with ESI data using unique accession numbers. The number of highly cited studies was counted based on the fractional counting method. Data were analyzed from January through July 2023.The number of publications by research field, country, and institutional affiliation.The number of published COVID-19-related highly cited studies was 14 studies in January to February 2020, peaked at 1292 studies in November to December 2021, and showed a downward trend thereafter, reaching 649 studies in November to December 2022. China had the highest number of highly cited studies per 2-month period until July to August 2020 (138.3 studies vs 103.7 studies for the US, the second highest country), and the US had the greatest number of highly cited studies afterward (159.9 studies vs 157.6 studies for China in September to October 2020). Subsequently, the number of highly cited studies per 2-month period published by China declined (decreasing from 179.7 studies in November to December 2020 to 40.7 studies in September to October 2022), and the UK produced the second largest number of such studies in May to June 2021 (171.3 studies). Similarly, the top 5 institutional affiliations in May to June 2020 by highly cited studies per 2-month period were from China (Huazhong University: 14.7 studies; University of Hong Kong: 6.8 studies; Wuhan University: 4.8 studies; Zhejiang University: 4.5 studies; Fudan University: 4.5 studies), while in November to December 2022, the top 5 institutions were in the US and UK (Harvard University: 15.0 studies; University College London: 11.0 studies; University of Oxford: 10.2 studies; University of London: 9.9 studies; Imperial College London: 5.8 studies).This study found that the total number of highly cited studies related to COVID-19 peaked at the end of 2021 and showed a downward trend until the end of 2022, while the origin of these studies shifted from China to the US and UK.
Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Authors: T. Conroy, P. Pfeiffer, V. Vilgrain, A. Lamarca, T. Seufferlein, E.M. O’Reilly, T. Hackert, T. Golan, G. Prager, K. Haustermans, A. Vogel, M. Ducreux
Journal: Annals of Oncology (2023)
Antimullerian Hormone, a Marker of Ovarian Reserve, Is Protective Against Presence and Severity of NASH in Premenopausal Women
Authors: Stephanie S. Maldonado, Marcelle I. Cedars, Katherine P. Yates, Laura A. Wilson, Ryan Gill, Norah A. Terrault, Ayako Suzuki, Monika A. Sarkar
Journal: Clinical Gastroenterology and Hepatology (2023)
Neuroprotective Effects of Microglial Membrane‐Derived Biomimetic Particles for Spinal Cord Injury
Authors: Wenjing Wang, Shang Li, Haiyan Li, Peilin Guo, Chengliang Lyu, Peng Ye, Weiqiang Yang, Jinghui Wang, Dingle Yu, Guihong Lu, Hui Tan
Journal: Advanced Healthcare Materials (2023)

Inhibition of oxidative stress and inflammatory responses caused by secondary injury following traumatic spinal cord injury (SCI) is an attractive strategy in treating traumatic SCI. However, the efficacy of drugs is severely limited owing to the poor penetration of the blood spinal cord barrier (BSCB). Here, inspired by cell chemotaxis and related chemokines production at the lesion sites of SCI, the microglial membrane is selected to construct a drug delivery system with the ability to cross the BSCB and target the lesions. PR@MM is prepared based on the assembly of polylactic-co-glycolic acid (PLGA) and resveratrol (RSV) followed by microglial membrane (MM) coating. Compared to that of the uncoated nanoparticles, the enrichment of PR@MM at the lesion sites of SCI increases, which is beneficial to achieve lesion targeting of RSV and exert therapeutic functions. Both in vitro and in vivo experiments demonstrate that PR@MM has the ability to scavenge reactive oxygen species and anti-inflammatory effects, which ultimately promotes the recovery of locomotory function after SCI. Therefore, this microglial membrane-based drug delivery system provides a promising biomimetic nanomedicine for targeted therapy for SCI.
Novel Natural Carrier‐Free Self‐Assembled Nanoparticles for Treatment of Ulcerative Colitis by Balancing Immune Microenvironment and Intestinal Barrier
Authors: Shan Gao, Haocheng Zheng, Shujing Xu, Jingwei Kong, Feng Gao, Zhijia Wang, Yuan Li, Ziqi Dai, Xinqi Jiang, Xia Ding, Haimin Lei
Journal: Advanced Healthcare Materials (2023)

Abstract Ulcerative colitis (UC) is a chronic inflammatory illness affecting the colon and rectum, with current treatment methods being unable to meet the clinical needs of ulcerative colitis patients. Although nanomedicines are recognized as promising anti‐inflammatory medicines, their clinical application is limited by their high cost and unpredictable safety risks. This study reveals that two natural phytochemicals, berberine (BBR) and hesperetin (HST), self‐assemble directly to form binary carrier‐free multi‐functional spherical nanoparticles (BBR‐HST NPs) through noncovalent bonds involving electrostatic interactions, π–π stacking, and hydrogen bonding. Because of their synergistic anti‐inflammatory activity, berberine–hesperetin nanoparticles (BBR‐HST NPs) exhibit significantly better therapeutic effects on UC and inhibitory effects on inflammation than BBR and HST at the same dose by regulating the immune microenvironment and repairing the damaged intestinal barrier. Furthermore, BBR‐HST NPs exhibit good biocompatibility and biosafety. Thus, this study proves the potential of novel natural anti‐inflammatory nanoparticles as therapeutic agents for UC, which could promote the progress of drug development for UC and eventually benefit patients who suffering from it.
Comment on ‘Treatment of moderate-to-severe alopecia areata with baricitinib in preadolescent children’
Authors: Michael G Buontempo, Kristen Lo Sicco, Jerry Shapiro
Journal: British Journal of Dermatology (2023)

In this response to a recent article on the off-label use of baricitinib for paediatric alopecia areata (AA), we raise additional points regarding the relationship between viral infections and AA relapse on Janus kinase inhibitor (JAKi) therapy, and the potential benefits of concomitant oral minoxidil therapy in mitigating the risk of relapse during JAKi dose reduction or discontinuation.
FDG-Avid Malakoplakia of the Ureter Mimicking Malignancy
Authors: Qian Zhao, Aisheng Dong, Changjing Zuo, Haige Chen
Journal: Clinical Nuclear Medicine (2023)

Malacoplakia is a rare chronic granulomatous disease and frequently associated with Escherichia coli infection. We describe the contrast-enhanced CT and FDG PET/CT findings in a case of bladder and ureteral malakoplakia with E. coli urinary tract infection. Contrast-enhanced CT showed multiple enhancing mural nodules in the bladder and left ureter, ranging from several millimeters to 3.1 cm. The ureteral nodules showed significantly increased FDG uptake with SUVmax of 20.4, due to histiocyte, lymphocyte, and plasma cell infiltrates revealed by histopathology.
Optimization of platelet‐rich fibrin
Authors: Richard J. Miron, Masako Fujioka‐Kobayashi, Anton Sculean, Yufeng Zhang
Journal: Periodontology 2000 (2023)

Abstract The use of platelet‐rich fibrin (PRF) has gained tremendous popularity in recent years owing to its ability to speed wound healing postsurgery. However, to date, many clinicians are unaware of methods designed to optimize the technology. This overview article will discuss the advancements and improvements made over the years aimed at maximizing cell and growth factor concentrations. First, a general understanding explaining the differences between RPM and RCF (g‐force) is introduced. Then, the low‐speed centrifugation concept, fixed angle versus horizontal centrifugation, and methods to maximize platelet concentrations using optimized protocols will be discussed in detail. Thereafter, the importance of chemically modified PRF tubes without the addition of chemical additives, as well as regulation of temperature to induce/delay clotting, will be thoroughly described. This article is a first of its kind summarizing all recent literature on PRF designed to optimize PRF production for clinical treatment.
Topical 188Re Ionizing Radiation Therapy Exerts High Efficacy in Curing Nonmelanoma Skin Cancer
Authors: Julia K. Tietze, Martin Heuschkel, Maila I. C. Krönert, Jens Kurth, Gesine Bandow, Gregor Ojak, Pavel Grünwald, Johanna Isabelle Herold, Alexander Thiem, Miriam Dreßler, Bernd J. Krause, Steffen Emmert, Sarah M. Schwarzenböck
Journal: Clinical Nuclear Medicine (2023)

Nonmelanoma skin cancer (NMSC) is the most frequent malignancy. Surgical intervention is the common treatment but may lead to disappointing results; alternative treatment options are needed.In this monocentric pilot study, topical 188Re resin was investigated as a treatment for invasive NMSC up to 3-mm thickness. Twenty-two patients with 40 histologically confirmed NMSCs with a median size of 1.25 cm2 (range, 0.04-16.8 cm2) and a median tumor thickness of 0.35 mm (range, 0.1-2.1 mm) were included. Patients were treated once with 188Re resin with a targeted dose of 50 Gy. The median applied activity was 111.4 MBq (range, 21.0-168.0 MBq), and the median treatment time was 89 minutes (range, 38-175 minutes). The response rate, adverse events, and cosmetic outcome were assessed at 14 days, 4 months, and 12 months.Response rate at 12 months was 97.5%, with 95% complete responses (clinically or histologically proven in case of clinical doubt). Most adverse events were reported at 14 days, with 20% itching and 12.5% mostly minor pain. Forty-nine percent of the lesions showed hypopigmentation only at 12 months. Forty-one percent of the lesions were graded as cosmetically superior to the expected result after surgery and 51.3% as comparable to successful surgery. The cosmetic outcome on the head and face was superior compared with the trunk and leg (P = 0.003).188Re resin is a highly effective treatment for NMSC up to 3-mm thickness and a valid alternative to surgery, specifically for tumors located on sensitive areas such as nose or ear.
Impact of newborn screening for SCID on the management of congenital athymia
Authors: Evey Howley, Zainab Golwala, Matthew Buckland, Federica Barzaghi, Sujal Ghosh, Scott Hackett, Rosie Hague, Fabian Hauck, Ursula Holzer, Adam Klocperk, Minna Koskenvuo, Nufar Marcus, Antonio Marzollo, Malgorzata Pac, Jan Sinclair, Carsten Speckmann, Maarja Soomann, Lynne Speirs, Sneha Suresh, Sophie Taque, Joris van Montfrans, Horst von Bernuth, Brynn K. Wainstein, Austen Worth, E. Graham Davies, Alexandra Y. Kreins
Journal: Journal of Allergy and Clinical Immunology (2023)

Newborn screening (NBS) programs for severe combined immunodeficiency facilitate early diagnosis of severe combined immunodeficiency and promote early treatment with hematopoietic stem cell transplantation, resulting in improved clinical outcomes. Infants with congenital athymia are also identified through NBS because of severe T-cell lymphopenia. With the expanding introduction of NBS programs, referrals of athymic patients for treatment with thymus transplantation have recently increased at Great Ormond Street Hospital (GOSH) (London, United Kingdom).
Extreme temperatures exacerbated oxidative stress and airway inflammation in a mouse model of allergic asthma
Authors: Chan Lu, Faming Wang, Zipeng Qiao, Miaomiao Deng, Qin Liu, Xu Yang
Journal: Allergy (2023)

The data that support the findings of this study are available from the corresponding author upon reasonable request. Figure S1 Figure S2 Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Readmission Rates After Acute Respiratory Distress Syndrome in Children
Authors: Garrett Keim, Jesse Y. Hsu, Neethi P. Pinto, Megan L. McSherry, Annie Laurie Gula, Jason D. Christie, Nadir Yehya
Journal: JAMA Network Open (2023)

Importance An increasing number of children survive after acute respiratory distress syndrome (ARDS). The long-term morbidity affecting these survivors, including the burden of hospital readmission and key factors associated with readmission, is unknown. Objective To determine 1-year readmission rates among survivors of pediatric ARDS and to investigate the associations of 3 key index hospitalization factors (presence or development of a complex chronic condition, receipt of a tracheostomy, and hospital length of stay [LOS]) with readmission. Design, Setting, and Participants This retrospective cohort study used data from the commercial or Medicaid IBM MarketScan databases between 2013 and 2017, with follow-up data through 2018. Participants included hospitalized children (aged ≥28 days to &amp;amp;lt;18 years) who received mechanical ventilation and had algorithm-identified ARDS. Data analysis was completed from March 2022 to March 2023. Exposures Complex chronic conditions (none, nonrespiratory, and respiratory), receipt of tracheostomy, and index hospital LOS. Main Outcomes and Measures The primary outcome was 1-year, all-cause hospital readmission. Univariable and multivariable Cox proportional hazard models were created to test the association of key hospitalization factors with readmission. Results One-year readmission occurred in 3748 of 13 505 children (median [IQR] age, 4 [0-14] years; 7869 boys [58.3%]) with mechanically ventilated ARDS who survived to hospital discharge. In survival analysis, the probability of 1-year readmission was 30.0% (95% CI, 29.0%-30.8%). One-half of readmissions occurred within 61 days of discharge (95% CI, 56-67 days). Both respiratory (adjusted hazard ratio [aHR], 2.69; 95% CI, 2.42-2.98) and nonrespiratory (aHR, 1.86; 95% CI, 1.71-2.03) complex chronic conditions were associated with 1-year readmission. Placement of a new tracheostomy (aHR, 1.98; 95% CI, 1.69-2.33) and LOS 14 days or longer (aHR, 1.87; 95% CI, 1.62-2.16) were associated with readmission. After exclusion of children with chronic conditions, LOS 14 days or longer continued to be associated with readmission (aHR, 1.92; 95% CI, 1.49-2.47). Conclusions and Relevance In this retrospective cohort study of children with ARDS who survived to discharge, important factors associated with readmission included the presence or development of chronic medical conditions during the index admission, tracheostomy placement during index admission, and index hospitalization of 14 days or longer. Future studies should evaluate whether postdischarge interventions (eg, telephonic contact, follow-up clinics, and home health care) may help reduce the readmission burden.
MicroRNA-200b-mediated reversion of a spectrum of epithelial-to-mesenchymal transition states in recessive dystrophic epidermolysis bullosa squamous cell carcinomas
Authors: Julia Illmer, Roland Zauner, Josefina Piñón Hofbauer, Monika Wimmer, Stefanie Gruner, Michael Ablinger, Johannes Bischof, Sonja Dorfer, Stefan Hainzl, Vanessa Tober, Shir Bergson, Ofer Sarig, Liat Samuelov, Christina Guttmann-Gruber, Ruby Shalom-Feuerstein, Eli Sprecher, Ulrich Koller, Martin Laimer, Johann W Bauer, Verena Wally
Journal: British Journal of Dermatology (2023)

Abstract Background Cutaneous squamous cell carcinoma (SCC) is the leading cause of death in patients with recessive dystrophic epidermolysis bullosa (RDEB). However, the survival time from first diagnosis differs between patients; some tumours spread particularly fast, while others may remain localized for years. As treatment options are limited, there is an urgent need for further insights into the pathomechanisms of RDEB tumours, to foster therapy development and support clinical decision-making. Objectives To investigate differences in RDEB tumours of diverging aggressiveness at the molecular and phenotypic level, with a particular focus on epithelial-to-mesenchymal (EMT) transition states and thus microRNA-200b (miR-200b) as a regulator. Methods Primary RDEB-SCC keratinocyte lines were characterized with respect to their EMT state. For this purpose, cell morphology was classified and the expression of EMT markers analysed using immunofluorescence, flow cytometry, semi-quantitative reverse transcriptase polymerase chain reaction and Western blotting. The motility of RDEB-SCC cells was determined and conditioned medium of RDEB-SCC cells was used to treat endothelial cells in an angiogenesis assay. In addition, we mined previously generated microRNA (miRNA) profiling data to identify a candidate with potential therapeutic relevance and performed transient miRNA transfection studies to investigate the candidate’s ability to reverse EMT characteristics. Results We observed high variability in EMT state in the RDEB-SCC cell lines, which correlated with in situ analysis of two available patient biopsies and respective clinical disease course. Furthermore, we identified miR-200b-3p to be downregulated in RDEB-SCCs, and the extent of deregulation significantly correlated with the EMT features of the various tumour lines. miR-200b-3p was reintroduced into RDEB-SCC cell lines with pronounced EMT features, which resulted in a significant increase in epithelial characteristics, including cell morphology, EMT marker expression, migration and angiogenic potential. Conclusions RDEB-SCCs exist in different EMT states and the level of miR-200b is indicative of how far an RDEB-SCC has gone down the EMT path. Moreover, the reintroduction of miR-200b significantly reduced mesenchymal features.
Topical treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials
Authors: Derek K. Chu, Alexandro W.L. Chu, Daniel G. Rayner, Gordon H. Guyatt, Juan José Yepes-Nuñez, Luis Gomez-Escobar, Lucia C. Pérez-Herrera, Juan Pablo Díaz Martinez, Romina Brignardello-Petersen, Behnam Sadeghirad, Melanie M. Wong, Renata Ceccacci, Irene X. Zhao, John Basmaji, Margaret MacDonald, Xiajing Chu, Nazmul Islam, Ya Gao, Ariel Izcovich, Rachel N. Asiniwasis, Mark Boguniewicz, Anna De Benedetto, Korey Capozza, Lina Chen, Kathy Ellison, Winfred T. Frazier, Matthew Greenhawt, Joey Huynh, Jennifer LeBovidge, Peter A. Lio, Stephen A. Martin, Monica O’Brien, Peck Y. Ong, Jonathan I. Silverberg, Jonathan M. Spergel, Wendy Smith Begolka, Julie Wang, Kathryn E. Wheeler, Donna D. Gardner, Lynda Schneider
Journal: Journal of Allergy and Clinical Immunology (2023)